David Lee Vollmer

US Patent:

20030092774, May 15, 2003

Filed:

Oct 11, 2002

Appl. No.:

10/270273

Inventors:

Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
Lindsay Lloyd - Salt Lake City UT, US
David Vollmer - West Jordan UT, US

International Classification:

A61K031/075
A61K031/66

US Classification:

514/720000, 514/130000

Abstract:

A method for treating neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularities of the eye and/or joint of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular and/or joint area having a neoplastic, angiogenic, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularity; providing a combretastatin-A4 based medicament, wherein the combretastatin-A4 based medicament is capable of preventing microtubule assembly, inhibiting the proliferation of endothelial, eukaryotic, and neoplastic cells, or altering their shape and function, as well as providing an anti-inflammatory effect; associating a therapeutically effective concentration of the combretastatin based medicament with the affected ocular and/or joint area of the living subject; and decreasing the neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic and/or constitutional irregularity of the eye and/or joint of the living subject.

US Patent:

20060004076, Jan 5, 2006

Filed:

Jun 3, 2005

Appl. No.:

11/145024

Inventors:

Dinesh Patel - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
John Gebhard - Salt Lake City UT, US

International Classification:

A61K 31/415
A61K 31/202

US Classification:

514406000, 514560000, 514547000

Abstract:

The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with at least one other pharmaceutically active agent to reduce inflammation.

US Patent:

20060122160, Jun 8, 2006

Filed:

Nov 8, 2005

Appl. No.:

11/270326

Inventors:

Dinesh Patel - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
John Gebhard - Salt Lake City UT, US

International Classification:

A61K 31/57
A61K 31/365

US Classification:

514171000, 514468000

Abstract:

The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with a parthenolide to reduce inflammation.

US Patent:

20060142253, Jun 29, 2006

Filed:

Feb 21, 2006

Appl. No.:

11/359925

Inventors:

Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
Lindsay Lloyd - Salt Lake City UT, US
David Vollmer - West Jordan UT, US

International Classification:

A61K 31/66

US Classification:

514130000

Abstract:

A method for treating neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularities of the eye and/or joint of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular and/or joint area having a neoplastic, angiogenic, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularity; providing a combretastatin-A4 based medicament, wherein the combretastatin-A4 based medicament is capable of preventing microtubule assembly, inhibiting the proliferation of endothelial, eukaryotic, and neoplastic cells, or altering their shape and function, as well as providing an anti-inflammatory effect; associating a therapeutically effective concentration of the combretastatin based medicament with the affected ocular and/or joint area of the living subject; and decreasing the neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic and/or constitutional irregularity of the eye and/or joint of the living subject.

US Patent:

20060154908, Jul 13, 2006

Filed:

Jan 26, 2006

Appl. No.:

11/342276

Inventors:

Dinesh Patel - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
John Gebhard - Salt Lake City UT, US

International Classification:

A61K 31/57

US Classification:

514171000

Abstract:

The present invention is drawn to compositions and methods for treating depression in a subject comprising co-administering therapeutically effective amounts of a DHEA congener and a second antidepressant agent to the subject, wherein the step of co-administrating is more effective in producing an anti-depressive effect compared to the administration of either the DHEA congener or the second antidepressant agent alone at their respective dosages.

US Patent:

20060217355, Sep 28, 2006

Filed:

Mar 6, 2006

Appl. No.:

11/370218

Inventors:

Dinesh Patel - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
John Gebhard - Salt Lake City UT, US

International Classification:

A61K 31/53
A61K 31/365
A61K 31/415

US Classification:

514171000, 514406000, 514471000

Abstract:

The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with at least one other pharmaceutically active agent to treat or prevent cancer.

US Patent:

20080233135, Sep 25, 2008

Filed:

Mar 14, 2008

Appl. No.:

12/077060

Inventors:

John R. Gebhard - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
Dinesh Patel - Salt Lake City UT, US

International Classification:

A61K 47/48
A61K 31/714
C07H 23/00
A61P 35/00

US Classification:

4241781, 514 52, 536 264, 5303871

Abstract:

The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.

US Patent:

20120015900, Jan 19, 2012

Filed:

Jul 22, 2011

Appl. No.:

13/188903

Inventors:

John R. Gebhard - Cottonwood Heights UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
Dinesh Patel - Salt Lake City UT, US

Assignee:

Osiris Therapeutics, Inc. - Columbia MD

International Classification:

A61K 31/714
A61P 35/00
A61P 35/02
C07H 23/00

US Classification:

514 52, 536 264

Abstract:

The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.